Long-term follow-up of lower dose dasatinib (50 mg daily)

Conclusions: These updated results continue to support 50 mg of dasatinib daily as an effective and safe dose for newly diagnosed early CML-CP.

https://pubmed.ncbi.nlm.nih.gov/31553487/